In SCLC-resistant xenograft mouse models, the EZH2 inhibitor EPZ011989 restores tumor sensitivity to irinotecan by upregulating SLFN11, and its combination with irinotecan significantly inhibits tumor growth (90). This evidence concerns the gene SLFN11 and neoplasm.